Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Thejew on Jul 14, 2019 2:37am

254 Views

Post# 29917748

Canopy

Check out this Canopy connection to Antibe Therapeutics, who is releasing their data soon and could be a huge play....Rami is on their Business Development Board and focuses on buyouts and partnerships. Hhhhmmmmm

Rami Batal PhD, MBA

- Former VP, Business Development for Purdue Canada;

brings to Antibe vast experience in the pain markets

- Currently VP, Medical Research of Canopy Growth, a

leading cannabis producer and innovator

https://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20July%202019.pdf

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December